NOVARTIS AG

Novartis AG is an innovative medicines company focused on the research, development, manufacturing, distribution, and commercialization of prescription pharmaceutical products. Its operations are organized into five primary units: Biomedical Research, Development, Operations, and two geographic commercial divisions for the United States and International markets. The firm targets four principal therapeutic areas: cardiovascular, renal, and metabolic disorders; immunology; neuroscience; and oncology. Prominent marketed treatments include Entresto for heart failure, Cosentyx for systemic inflammatory conditions, Kisqali for breast cancer, Kesimpta for relapsing multiple sclerosis, and radioligand therapies like Pluvicto. Novartis supplies these medicinal products directly and through commercial operations to healthcare systems and patients worldwide.

The enterprise maintains its global corporate headquarters and registered office in Basel, Switzerland. Operating at global scale, Novartis sells its pharmaceutical products across approximately 120 countries. As of December 31, 2025, the organization employed 75,267 full-time equivalent employees to conduct its international research, manufacturing, IT, procurement, and commercialization activities.

Summary of the business section of Novartis's latest annual report, written by StockData.

“We have 17 491 full-time equivalent field force employees, as of December 31, 2025, including supervisors and administrative personnel.”